| Standard dosage | 250–500 mg every 12 hours |
| Contraindications | Absolute: Prolonged QT interval, significant renal impairment |
| Relative: Significant bradycardia, hypokalemia, hypomagnesemia | |
| Main drug interactions | Thiazide diuretics, macrolides, antifungals, phenothiazines, quinolones, verapamil (risk of QT prolongation) |
| Main side effects | QT prolongation and torsade de pointes/ventricular arrhythmias |
| Special points | Class III agent (potassium channel blocker). |
| Especially useful in patients with heart failure. | |
| Prescribing rights restricted to authorized users. | |
| Cost/cost-effectiveness | Non-generic (approximate cost $245 per month). First 5 doses must be administered inpatient with careful monitoring of QT interval. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.